Morphosys Ag (MOR) has released an update.
MorphoSys AG has officially completed its voluntary delisting of shares from the Frankfurt Stock Exchange and American Depositary Shares from Nasdaq, following its acquisition by Novartis AG. The company’s minority shareholders are set to have their shares transferred to Novartis in exchange for a cash compensation, with a resolution expected at the upcoming Annual General Meeting. MorphoSys, a biopharmaceutical firm focused on cancer treatment, continues its operations with a commitment to innovate in the medical field.
For further insights into MOR stock, check out TipRanks’ Stock Analysis page.
